Edition:
United States

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

16.31USD
14 Dec 2017
Change (% chg)

$-0.43 (-2.57%)
Prev Close
$16.74
Open
$17.00
Day's High
$17.19
Day's Low
$16.06
Volume
74,596
Avg. Vol
55,487
52-wk High
$26.74
52-wk Low
$13.54

Summary

Name Age Since Current Position

Mark Iwicki

50 2017 Chairman of the Board, President, Chief Executive Officer

Mary Reumuth

42 2017 Chief Financial Officer, Treasurer

Todd Bazemore

47 2017 Chief Operating Officer

Vincent Kosewski

54 2017 Senior Vice President - Manufacturing and Supply Chain Management

Michele LaRussa

47 2016 Senior Vice President - Regulatory Affairs and Quality Assurance

Hongming Chen

46 2014 Chief Scientific Officer

Kim Brazzell

64 2013 Chief Medical Officer

Gregory Grunberg

44 2016 Independent Director

Paulina Hill

35 2017 Independent Director

Andrew Koven

58 2017 Independent Director

Robert Langer

68 2009 Independent Director

Robert Paull

41 2009 Independent Director

Howard Rosen

59 2015 Independent Director

Rajeev Shah

40 2015 Independent Director

Robert Tepper

62 2009 Independent Director

Chen Yu

43 2016 Independent Director

Biographies

Name Description

Mark Iwicki

Mr. Mark T. Iwicki is Chairman of the Board, President, Chief Executive Officer of the Company. Previously, Mr. Iwicki served as Executive Chairman of the Board from April 2015 to September 2015. Prior to joining the Company, Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics, Inc., or Civitas, a biopharmaceutical company which was acquired by Acorda Therapeutics, from January 2014 to November 2014. Prior to Civitas, Mr. Iwicki served as President and Chief Executive Officer at Blend Therapeutics, Inc., or Blend, a biopharmaceutical company, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was President and Chief Executive Officer of Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.), or Sunovion, a pharmaceutical company. Mr. Iwicki was at Sepracor/Sunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was Vice President and Business Unit Head at Novartis Pharmaceuticals Corporation. He was at Novartis from March 1998 to October 2007. Prior to that, Mr. Iwicki held management positions at Astra Merck Inc. and Merck & Co., Inc. In addition to serving on the Company’s Board, Mr. Iwicki also currently serves on the boards of AimmuneTherapeutics, Inc., Merus N.V. and Pulmatrix Inc., all public companies, and privately held companies Nimbus Therapeutics, Inc., Taris Biomedical LLC, and Oxeia Biopharmaceuticals, Inc. Mr. Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University.

Mary Reumuth

Ms. Mary Reumuth CPA serves as Chief Financial Officer, Treasurer of the Company. She has served as our Chief Financial Officer since July 2017, Senior Vice President, Finance from February 2017 to July 2017, our Vice President, Finance from December 2014 to February 2017, our Senior Director, Finance from February 2014 to December 2014, as our Corporate Controller from February 2014 to July 2017 and Treasurer since February 2014. Prior to joining us, Ms. Reumuth acted as an independent financial consultant from November 2012 to January 2014 and, prior to that, served as Corporate Controller for Enobia Pharma Corp., or Enobia, a global biopharmaceutical company acquired by Alexion Pharmaceuticals, Inc., from May 2011 to June 2012. Prior to Enobia, Ms. Reumuth served as Director of Finance at Verenium Corporation, or Verenium, a biotechnology company, from December 2007 to March 2011. Ms. Reumuth held a variety of finance and accounting positions at Genzyme Corporation, or Genzyme, (now a Sanofi Company), and ILEX Oncology, Inc., or ILEX (acquired by Genzyme) from 2001 to 2007. Prior to ILEX, Ms. Reumuth was an auditor at Ernst & Young LLP. Ms. Reumuth earned her Bachelor's degree in Business Administration from Texas A&M University—Corpus Christi, and is a Certified Public Accountant.

Todd Bazemore

Mr. Todd M. Bazemore is appointed as Chief Operating Officer of the company effective November 20, 2017. He has served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc., a subsidiary of Santhera Pharmaceuticals Holdings AG from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp., a biopharmaceutical company focused on orphan diseases, between April 2014 and January, 2016, when Dyax was acquired by Shire plc. At Dyax, Mr. Bazemore oversaw all aspects of Dyax’s commercial department including sales, marketing, commercial analytics, market access and patient services. Between April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc. (now Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company focused on serious medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of Respiratory Business Unit. He received his Bachelors of Science from the University of Massachusetts, Lowell.

Vincent Kosewski

Mr. Vincent Kosewski serves as Senior Vice President - Manufacturing and Supply Chain Management of the Company since July 2017. Prior to joining us, Mr. Kosewski served as Vice President, Supply Chain Operations at Sunovion Pharmaceuticals Inc. from October 2010 to June 2017. He was also Vice President and General Manager at Sunovion's manufacturing subsidiary, Sepracor Canada Ltd., from 2010 to 2015. Prior to joining Sunovion, Mr. Kosewski held several positions at Sepracor, Inc., including Vice President, Supply Chain Operations from 2007 to 2010. Mr. Kosewski began his pharmaceutical career at Astra USA, Inc., holding positions in quality assurance, manufacturing, procurement and business development. Mr. Kosewski holds a B.S. in Chemistry from Fairfield University and an M.B.A. from Bryant University.

Michele LaRussa

Ms. Michele LaRussa serves as Senior Vice President - Regulatory Affairs and Quality Assurance of the Company since October 2016. Prior to joining us, Ms. LaRussa served as Global Head of Regulatory Affairs, Dermatology at GlaxoSmithKline plc from July 2012 to September 2016, where she led a cross-functional, multi-national team to develop new chemical entities and integrate groups and technologies from a recent acquisition into GlaxoSmithKline's existing structure, and at Allergan from September 2007 to June 2012, where she led the review and approval procedures for three new chemical entities. Ms. LaRussa spent much of her career with Novartis (including CIBA Vision Ophthalmics, Inc, Novartis Ophthalmics AG, and Novartis AG) with increasing levels of responsibility in regulatory affairs from October 1994 to July 2007, including leading the Regulatory Affairs Dermatology Department, holding lead responsibility for BOTOX, Latisse and Aczone and submitting and gaining approval for an additional indication for BOTOX. Ms. LaRussa received a B.S. in Chemistry from the University of South Florida.

Hongming Chen

Dr. Hongming Chen, Sc.D. is Chief Scientific Officer of the Company. Prior to that, Dr. Chen has served as our Chief Scientific Officer since October 2014. Prior to that, Dr. Chen served as our Executive Vice President of Research from October 2013 to October 2014 and our Vice President of Research from January 2010 to October 2013. Prior to joining us, Dr. Chen served as Director of Formulation Development at TransForm Pharmaceuticals Inc., or TransForm, from 2000 to January 2010. Before joining TransForm, Dr. Chen conducted vaccine delivery research and development at AstraZeneca plc from 1997 to 2000, and at Merck & Co., Inc. from 1996 to 1997. In 2015, Dr. Chen was elected to the College of Fellows at the American Institute for Medical and Biological Engineering. Dr. Chen received a B.S. in Chemical Engineering from The University of Texas at Austin in 1992 and both an M.S. and a Sc.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Kim Brazzell

Dr. Kim Brazzell, Ph.D. serves as Chief Medical Officer of Kala Pharmaceuticals, Inc. He has served as our Chief Medical Officer since February 2013. He has also served as a Principal of Acuity Advisors, LLC, an ophthalmic consulting company, since January 2014. Dr. Brazzell served as Chief Medical Officer of Mimetogen Pharmaceuticals, Inc., a clinical stage biotechnology company, from January 2012 until December 2015. Dr. Brazzell also held several executive positions at Inspire Pharmaceuticals, Inc., or Inspire, a specialty pharmaceutical company focusing on ophthalmic products, including Executive Vice President of Medical and Scientific Affairs from 2010 to 2011, Executive Vice President and Head of Ophthalmology Business from 2009 to 2010, and Senior Vice President of Ophthalmic Research and Development from 2004 to 2008. Prior to joining Inspire, Dr. Brazzell served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics AG from 2000 to 2004. Dr. Brazzell also served as Vice President, R&D at Ciba Vision Ophthalmics, Inc. and as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in Pharmacy and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky.

Gregory Grunberg

Dr. Gregory Grunberg, M.D., serves as Independent Director of the Company. He has served as a member of our board of directors since April 2016. Dr. Grunberg has been a Managing Director at Longitude Capital Management Co., LLC, or Longitude, since 2012 and has focused on medical technology and drug development. Prior to joining Longitude, Dr. Grunberg was a Principal at Rho Ventures and an Engagement Manager at McKinsey & Company. Dr. Grunberg serves as a director of BAROnova and California Cryobank, Inc., and has previously served as a director of AqueSys, Inc. and as a Board Observer at SARCode Bioscience Inc. and PHT Corporation. Dr. Grunberg is Board Certified in Internal Medicine and completed his residency at Cornell's New York Presbyterian Hospital. He has maintained a limited clinical practice in Internal Medicine and affiliations with University of California, San Francisco and Kaiser Permanente. Dr. Grunberg received an M.D. and an M.B.A. from Duke University, where he was a Fuqua Scholar, and an A.B. degree from Amherst College.

Paulina Hill

Dr. Paulina Hill, Ph.D., serves as Independent Director of the Company. She has served as a member of our board of directors since June 2017. Dr. Hill is a principal at Polaris Partners, or Polaris, where she has been since 2012 and has focused on investments in healthcare. Prior to joining Polaris, Dr. Hill completed her postdoctoral fellowship in the Chemical Engineering department at the Massachusetts Institute of Technology. Dr. Hill served as the founding chief executive officer of Marauder Therapeutics, a biotechnology company based in Cambridge, Massachusetts. Paulina serves on the boards of the private companies Arsenal Medical, Faraday Pharmaceuticals, KinDex Pharmaceuticals, Marauder Therapeutics and Neuronetics. She is an observer on the boards of the private companies 480 Biomedical, Microchips Biotech and Sofregen. She also serves on the board of The Capital Network, a non-profit that provides fundraising education to entrepreneurs. Dr. Hill completed her Ph.D. in Molecular Medicine with a Tissue Engineering focus at Wake Forest University School of Medicine. Dr. Hill graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry.

Andrew Koven

Mr. Andrew Ian Koven is Independent Director of the Company. Mr. Koven is President and Chief Business Officer of Aralez Pharmaceuticals Inc., a public company, and served in this role with the company’s predecessor, POZEN Inc., since June 1, 2015. Prior to joining Pozen, Mr. Koven served as Chief Administrative Officer and General Counsel of Auxilium Pharmaceuticals Inc., a specialty biopharmaceutical company, from February 2012 until January 2015, when it was acquired by Endo International plc. In September 2011, Mr. Koven was appointed President and Chief Administrative Officer and a member of the board of directors of Neurologix. Mr. Koven resigned from Neurologix in November 2011, primarily due to the company’s inability to raise sufficient capital to continue its operations (including its inability to compensate Mr. Koven for his services). Neurologix filed for protection under Chapter 7 of the U.S. Bankruptcy Code on March 16, 2012. Before Neurologix, Mr. Koven served as Executive Vice President and Chief Administrative and Legal Officer of Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company, from July 2010 until May 2011 when it was acquired by Merck & Co., Inc. Previously, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc., a specialty pharmaceutical company, from March 2007 until February 2010 when it was acquired by Dainippon Sumitomo Pharma Co., Ltd. Prior to joining Sepracor, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Kos Pharmaceuticals, Inc., a specialty pharmaceutical company, from August 2003 until its acquisition by Abbott Laboratories in December 2006. Mr. Koven began his career in the pharmaceutical industry first as an Assistant General Counsel and then as Associate General Counsel at Warner-Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003.

Robert Langer

Dr. Robert S. Langer, Jr. Sc.D., serves as Independent Director of the Company since December 2009. Dr. Langer has been an Institute Professor at the Massachusetts Institute of Technology, or MIT, since 2005, and prior to that was a Professor at MIT since 1977. Dr. Langer received his B.S. from Cornell University and his Sc.D. from MIT both in Chemical Engineering. Dr. Langer currently serves on the board of directors of UK public company Puretech Health plc, and previously served on the board of directors of public companies Momenta Pharmaceuticals, Inc., from 2001 to 2009, Wyeth from 2004 to 2009, Fibrocell Science, Inc. from 2010 to 2012 and Millipore Corp. from 2009 to 2010. Dr. Langer also served as a director on the Food and Drug Administration Science Board from 1995 to 2002, including his service as chairman from 1999 to 2002.

Robert Paull

Mr. Robert Paull serves as Independent Director of the Company since July 2009. Mr. Paull is a Co-founder and Venture Partner at Lux Capital Management, or Lux Capital, where he has been since October 2004 and has focused on ventures in healthcare. In addition to joining Lux Capital, Mr. Paull served as our founding Chief Executive Officer, President and Treasurer from July 2009 to June 2012. Mr. Paull also served as founding Chief Executive Officer of Genocea Biosciences Inc., a vaccine discovery and development company, from August 2006 to February 2009, and is the co-founder of Lux Research, Inc., an emerging technology market research and consulting firm, which was founded in January 2004. Mr. Paull holds a B.S. in Architecture from the University of Virginia.

Howard Rosen

Mr. Howard B. Rosen serves as Independent Director of the Company. He has served as a member of our board of directors since January 2014. Since 2008, Mr. Rosen has served as a consultant to several companies in the biotechnology industry. He has also served as a lecturer at Stanford University in Chemical Engineering since 2009 and in Management since 2011. Mr. Rosen served as Chief Executive Officer of AcelRx Pharmaceuticals, Inc., or AcelRx, a public company developing products for pain relief, from April 2016 to March 2017, and Interim Chief Executive Officer from April 2015 to March 2016. Mr. Rosen also served as Interim President and Chief Executive Officer of Pearl Therapeutics, Inc. from June 2010 to March 2011. From 2004 to 2008, Mr. Rosen was Vice President of Commercial Strategy at Gilead Sciences, Inc., a biopharmaceutical company. Mr. Rosen was President of ALZA Corporation, a pharmaceutical and medical systems company that merged with Johnson & Johnson, a global healthcare company, in 2001, from 2003 until 2004. Prior to that, from 1994 until 2003, Mr. Rosen held various positions at ALZA Corporation. Mr. Rosen is chairman of the board of directors of AcelRx, a public company, and also serves on the board of directors of Alcobra, Ltd., a public company. Mr. Rosen is also currently a member of the board of directors of private biotechnology company Entrega, Inc. Mr. Rosen holds a B.S. in Chemical Engineering from Stanford University, an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and an M.B.A. from the Stanford Graduate School of Business.

Rajeev Shah

Mr. Rajeev M Shah serves as Independent Director of the Company since July 2015. Mr. Shah is a Managing Director and Portfolio Manager at RA Capital Management, LLC, or RA Capital. Prior to joining RA Capital in 2004, Mr. Shah was a Senior Project Leader at Altus Pharmaceuticals Inc., a spin-off of Vertex Pharmaceuticals Inc., from 2001 to 2004. Mr. Shah is currently a member of the board of directors of the public companies Ra Pharmaceuticals, Inc. and Kalvista Pharmaceuticals, Inc. Mr. Shah holds a B.A. in Chemistry from Cornell University.

Robert Tepper

Dr. Robert I. Tepper, M.D., serves as Independent Director of the Company since December 2009. Dr. Tepper is a General Partner of Third Rock Ventures, L.P., or Third Rock, which he co-founded in March 2007 and focuses on the formation, development and scientific strategy of Third Rock's portfolio companies, as well as actively identifying and evaluating new investments. Prior to joining Third Rock, Dr. Tepper served as President of Research and Development at Millennium Pharmaceuticals, Inc., or Millennium. Prior to joining Millennium in 1994, he served as principal investigator in the laboratory of tumor biology at the Massachusetts General Hospital Cancer Center. Dr. Tepper is also a founder and former member of the scientific advisory board of Cell Genesys/Abgenix Inc. Dr. Tepper serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several healthcare institutions, including the Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical School. Dr. Tepper is a board member of the public company Jounce Therapeutics, Inc. and was previously a board member of the public company bluebird bio, Inc. from 2010 to 2015. Dr. Tepper is currently a board member of private life sciences companies Allena Pharmaceuticals, Inc., Constellation Pharmaceuticals Inc. and Neon Therapeutics, Inc. Dr. Tepper also serves on the board of overseers at Tufts University and on the Council of the National Center for Advancing Translational Sciences at the National Institutes of Health. Dr. Tepper holds an A.B. in biochemistry from Princeton University and an M.D. from Harvard Medical School.

Chen Yu

Dr. Chen Yu, M.D., serves as Independent Director of the Company ince April 2016. Dr. Yu has been a Managing Partner at Vivo Capital LLC, or Vivo, since 2011. Prior to joining Vivo in 2004, Dr. Yu worked at aQuantive, a private technology company. Dr. Yu has served as Chief Business Officer at China KangHui, a leading China based orthopedic company, and as Chief Operating Officer at Sagent Pharmaceuticals. Dr. Yu currently serves or has served on the boards of several private life science companies in both the United States and China, including SentreHeart, Rempex Pharmaceuticals, Nora Therapeutics, Jian Rui Bao Beijing GMT Science & Technology Development Co., Ltd, Outpost Medicine, LLC, PrinJohnson BioPharma, Inc., Nabriva Therapeutics, and Synaptic Medical. Dr. Yu currently serves on the California Leadership Council for the Nature Conservancy, an environmental non-profit with global reach, and was previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.